Coya Therapeutics (COYA) vs Foghorn Therapeutics (FHTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Coya Therapeutics (COYA) has outperformed Foghorn Therapeutics (FHTX) over the past year, losing 20.9% versus a loss of 55.8%. Foghorn Therapeutics is the larger company by market cap ($122.0 million vs $117.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | FHTX |
|---|---|---|
| Share price | $5.01 | $2.06 |
| Market cap | $117.41M | $122.04M |
| 1-day change | +0.30% | +3.27% |
| YTD return | -13.97% | -63.15% |
| 1-year return | -20.92% | -55.78% |
| 5-year return | — | -83.93% |
| EPS (TTM) | $-1.07 | $-0.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $7.61 |
| 52-week low | $3.71 | $1.79 |
| Distance from 52-week high | -35.42% | -73.00% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +203.90% | +191.97% |
| Average volume | 158.05K | 629.61K |
| Shares outstanding | 23.46M | 59.39M |
| Employees | 8 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COYA has outperformed FHTX by 34.9 percentage points over the past year.
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
COYA vs FHTX FAQ
Which is bigger, Coya Therapeutics or Foghorn Therapeutics?
Foghorn Therapeutics (FHTX) is larger, with a market capitalization of $122.04M compared with $117.41M for Coya Therapeutics (COYA).
Which stock has performed better over the past year, COYA or FHTX?
COYA returned -20.92% over the past 12 months, compared with -55.78% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and Foghorn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.